{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"TRIPLEX","nct_id":"NCT05223647","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=triplex-nct05223647. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TRIPLEX","arms":[{"description":"Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.\n\nThoracic radiotherapy of 30 Gy/10 fractions between 2nd and 3rd carboplatin/etoposide/durvalumab course.","label":"Chemo-immunotherapy plus thoracic radiotherapy","type":"EXPERIMENTAL"},{"description":"Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.","label":"Chemo-immunotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["St. Olavs Hospital","Haukeland University Hospital","University Hospital of North Norway","Alesund Hospital","Helse Stavanger HF","Oslo University Hospital","Helse Nord-Trøndelag HF","Helse Fonna","Drammen sykehus","University Hospital, Akershus","Erasmus Medical Center","Sahlgrenska University Hospital","Karolinska University Hospital","Gävle Hospital","Sykehuset Innlandet HF","North Estonia Medical Centre","Nordlandssykehuset HF","Landspitali University Hospital","Lund University Hospital","University Hospital, Linkoeping"],"completion_date":{"date":"2025-09-04","type":"ACTUAL"},"conditions":["Small-cell Lung Cancer"],"enrollment":{"count":239,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Thoracic radiotherapy","otherNames":[],"type":"PROCEDURE"},{"name":"Chemo-immunotherapy","otherNames":["carboplatin/etoposide/durvalumab"],"type":"DRUG"}],"last_update":"2026-01-28","lead_sponsor":"Norwegian University of Science and Technology","official_title":"Randomized Phase III Trial Investigating the Survival Benefit of Adding Thoracic Radiotherapy to Durvalumab (MEDI4736) Immunotherapy Plus Chemotherapy in Extensive Stage Small-cell Lung Cancer","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-09-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Change in 1-year overall survival","timeFrame":"14 months after last patient entry"}],"references":[],"start_date":{"date":"2022-01-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT05223647"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/triplex-nct05223647"}